Oral Semaglutide In The Management Of Type 2 Diabetes: A Report On The Evidence To Date

Sam Pearson,1,* Noppadol Kietsiriroje,1,2,* Ramzi A Ajjan1 1Leeds Institute of Cardiovascular and Metabolic Medicine, Faculty of Medicine and Health, University of Leeds, Leeds, West Yorkshire LS2 9JT, UK; 2Division of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicin...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Pearson S, Kietsiriroje N, Ajjan RA
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	oral semaglutide type 2 diabetes treatment glucagon-like peptide 1. Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/ea897ea817234a6793c6e8fcf10e6798
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ea897ea817234a6793c6e8fcf10e6798
record_format	dspace
spelling	oai:doaj.org-article:ea897ea817234a6793c6e8fcf10e67982021-12-02T09:25:23ZOral Semaglutide In The Management Of Type 2 Diabetes: A Report On The Evidence To Date1178-7007https://doaj.org/article/ea897ea817234a6793c6e8fcf10e67982019-12-01T00:00:00Zhttps://www.dovepress.com/oral-semaglutide-in-the-management-of-type-2-diabetes-a-report-on-the--peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Sam Pearson,1,* Noppadol Kietsiriroje,1,2,* Ramzi A Ajjan1 1Leeds Institute of Cardiovascular and Metabolic Medicine, Faculty of Medicine and Health, University of Leeds, Leeds, West Yorkshire LS2 9JT, UK; 2Division of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Hatyai, Songkhla 90110, Thailand*These authors contributed equally to this workCorrespondence: Ramzi A AjjanLeeds Institute of Cardiovascular and Metabolic Medicine, Faculty of Medicine and Health, University of Leeds, Leeds, West Yorkshire LS2 9JT, UKTel +44 113 343 7475Email r.ajjan@leeds.ac.ukAbstract: In recent years, newer drug classes for the treatment of type 2 diabetes mellitus have been released with significant effects on glucose lowering and weight reduction. One of the most promising classes in achieving these goals has been the glucagon-like peptide (GLP)-1 agonists. However, a difficulty with the use of these agents is the need for subcutaneous injections, which can be inconvenient to individuals living with type 2 diabetes. More recently, a GLP-1 agonist has been developed, semaglutide, that can be administered orally which has at least similar effects to the subcutaneous preparation from which this compound is derived. In this review article, we discuss the glycemic and cardiovascular effects of the GLP-1 agonists with special emphasis on oral semaglutide and the potential role of this therapy in individuals with type 2 diabetes.Keywords: oral semaglutide, type 2 diabetes, treatment, glucagon-like peptide 1  Pearson SKietsiriroje NAjjan RADove Medical Pressarticleoral semaglutidetype 2 diabetestreatmentglucagon-like peptide 1.Specialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 12, Pp 2515-2529 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	oral semaglutide type 2 diabetes treatment glucagon-like peptide 1. Specialties of internal medicine RC581-951
spellingShingle	oral semaglutide type 2 diabetes treatment glucagon-like peptide 1. Specialties of internal medicine RC581-951 Pearson S Kietsiriroje N Ajjan RA Oral Semaglutide In The Management Of Type 2 Diabetes: A Report On The Evidence To Date
description	Sam Pearson,1,* Noppadol Kietsiriroje,1,2,* Ramzi A Ajjan1 1Leeds Institute of Cardiovascular and Metabolic Medicine, Faculty of Medicine and Health, University of Leeds, Leeds, West Yorkshire LS2 9JT, UK; 2Division of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Hatyai, Songkhla 90110, Thailand*These authors contributed equally to this workCorrespondence: Ramzi A AjjanLeeds Institute of Cardiovascular and Metabolic Medicine, Faculty of Medicine and Health, University of Leeds, Leeds, West Yorkshire LS2 9JT, UKTel +44 113 343 7475Email r.ajjan@leeds.ac.ukAbstract: In recent years, newer drug classes for the treatment of type 2 diabetes mellitus have been released with significant effects on glucose lowering and weight reduction. One of the most promising classes in achieving these goals has been the glucagon-like peptide (GLP)-1 agonists. However, a difficulty with the use of these agents is the need for subcutaneous injections, which can be inconvenient to individuals living with type 2 diabetes. More recently, a GLP-1 agonist has been developed, semaglutide, that can be administered orally which has at least similar effects to the subcutaneous preparation from which this compound is derived. In this review article, we discuss the glycemic and cardiovascular effects of the GLP-1 agonists with special emphasis on oral semaglutide and the potential role of this therapy in individuals with type 2 diabetes.Keywords: oral semaglutide, type 2 diabetes, treatment, glucagon-like peptide 1
format	article
author	Pearson S Kietsiriroje N Ajjan RA
author_facet	Pearson S Kietsiriroje N Ajjan RA
author_sort	Pearson S
title	Oral Semaglutide In The Management Of Type 2 Diabetes: A Report On The Evidence To Date
title_short	Oral Semaglutide In The Management Of Type 2 Diabetes: A Report On The Evidence To Date
title_full	Oral Semaglutide In The Management Of Type 2 Diabetes: A Report On The Evidence To Date
title_fullStr	Oral Semaglutide In The Management Of Type 2 Diabetes: A Report On The Evidence To Date
title_full_unstemmed	Oral Semaglutide In The Management Of Type 2 Diabetes: A Report On The Evidence To Date
title_sort	oral semaglutide in the management of type 2 diabetes: a report on the evidence to date
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/ea897ea817234a6793c6e8fcf10e6798
work_keys_str_mv	AT pearsons oralsemaglutideinthemanagementoftype2diabetesareportontheevidencetodate AT kietsirirojen oralsemaglutideinthemanagementoftype2diabetesareportontheevidencetodate AT ajjanra oralsemaglutideinthemanagementoftype2diabetesareportontheevidencetodate
_version_	1718398156950994944

Oral Semaglutide In The Management Of Type 2 Diabetes: A Report On The Evidence To Date

Ejemplares similares